1-4 of 4
William S. Dalton, M.D., Ph.D.
Close
Sort by
Journal Articles

Phase I Study of Bortezomib(Bz), Pegylated Doxorubicin(DOX) and Dexamethasone(dex); ( VDD) with Escalating Doses of Cyclophosphamide(Cy) in Patients with Newly Diagnosed Myeloma.

Melissa Alsina, MD, Rachid Baz, MD, Jose L Ochoa, MD, Jyotishankar Raychaudhuri, Kara Kosakowski, Michelle Mintz, Kendra Anderson, William S Dalton, M.D., Ph.D, Daniel Sullivan
Journal: Blood
Blood (2009) 114 (22): 617.
https://doi.org/10.1182/blood.V114.22.617.617
Published: 2009
Journal Articles

β1 Integrin Adhesion Enhances IL-6 Mediated STAT3 Signaling in Multiple Myeloma Cells: Implications for Microenvironment Influence on Tumor Cell Survival and Proliferation.

Kenneth H Shain, M.D., Ph.D., Danielle Yarde, Mark Mead, Ph.D., Lori Hazlehurst, Ph.D., William S Dalton, M.D., Ph.D
Journal: Blood
Blood (2008) 112 (11): 1706.
https://doi.org/10.1182/blood.V112.11.1706.1706
Published: 2008
Journal Articles

NF-kB as a Regulator of FA/BRCA Gene Expression in Multiple Myeloma.

Vasco A. Oliveira, PhD, Linda Mathews, B.Sc., Danielle Yarde, B.Sc, Xingyu Wang, Ph.D., David Boulware, M.Sc., Lori A. Hazlehurst, Ph.D., Dung-Tsa Chen, Ph.D., Amer Beg, Ph.D., William S. Dalton, M.D., Ph.D.
Journal: Blood
Blood (2007) 110 (11): 3508.
https://doi.org/10.1182/blood.V110.11.3508.3508
Published: 2007
Journal Articles

Bortezomib-Induced Reversal of CAM-DR Phenotype in Myeloma Is Associated with AKT and ERK1/2 Signaling.

Ramadevi Nimmanapalli, Ph.D, Lori Hazlehurst, Ph.D, Steven Enkemann, Ph.D, Melissa Alsina, M.D., William S. Dalton, M.D., Ph.D
Journal: Blood
Blood (2004) 104 (11): 3357.
https://doi.org/10.1182/blood.V104.11.3357.3357
Published: 2004